Compare Barclays PLC (BCS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Viatris Inc — how do they compare? Barclays PLC trades at $28.05 (market cap $92.56B), while Viatris Inc trades at $16.48 (market cap $18.99B). The key difference: Barclays PLC is far larger — about 4.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| BCS | VTRS | |
|---|---|---|
Market Cap | $92.56B | $18.99B |
Sector | Financials | Health |
52-Week High | $28.41 | $17.39 |
52-Week Low | $18.48 | $8.74 |
Dividend Yield | 1.67% | 2.94% |
Enterprise Value | — | $31.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.
The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
